182 related articles for article (PubMed ID: 34021261)
1. A new technological approach in diagnostic pathology: mass spectrometry imaging-based metabolomics for biomarker detection in urachal cancer.
Neumann JM; Niehaus K; Neumann N; Knobloch HC; Bremmer F; Krafft U; Kellner U; Nyirády P; Szarvas T; Bednarz H; Reis H
Lab Invest; 2021 Sep; 101(9):1281-1288. PubMed ID: 34021261
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.
Reis H; Krafft U; Niedworok C; Módos O; Herold T; Behrendt M; Al-Ahmadie H; Hadaschik B; Nyirady P; Szarvas T
Dis Markers; 2018; 2018():7308168. PubMed ID: 29721106
[TBL] [Abstract][Full Text] [Related]
3. Molecular signatures of medullary thyroid carcinoma by matrix-assisted laser desorption/ionisation mass spectrometry imaging.
Smith A; Galli M; Piga I; Denti V; Stella M; Chinello C; Fusco N; Leni D; Manzoni M; Roversi G; Garancini M; Pincelli AI; Cimino V; Capitoli G; Magni F; Pagni F
J Proteomics; 2019 Jan; 191():114-123. PubMed ID: 29581064
[TBL] [Abstract][Full Text] [Related]
4. Subtyping non-small cell lung cancer by histology-guided spatial metabolomics.
Neumann JM; Freitag H; Hartmann JS; Niehaus K; Galanis M; Griesshammer M; Kellner U; Bednarz H
J Cancer Res Clin Oncol; 2022 Feb; 148(2):351-360. PubMed ID: 34839410
[TBL] [Abstract][Full Text] [Related]
5. De novo discovery of metabolic heterogeneity with immunophenotype-guided imaging mass spectrometry.
Prade VM; Kunzke T; Feuchtinger A; Rohm M; Luber B; Lordick F; Buck A; Walch A
Mol Metab; 2020 Jun; 36():100953. PubMed ID: 32278304
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Metabolite Biomarkers for Soft Tissue Sarcomas Discovered by Mass Spectrometry Imaging.
Lou S; Balluff B; Cleven AHG; Bovée JVMG; McDonnell LA
J Am Soc Mass Spectrom; 2017 Feb; 28(2):376-383. PubMed ID: 27873216
[TBL] [Abstract][Full Text] [Related]
7. Assessing the potential of sputtered gold nanolayers in mass spectrometry imaging for metabolomics applications.
Ràfols P; Vilalta D; Torres S; Calavia R; Heijs B; McDonnell LA; Brezmes J; Del Castillo E; Yanes O; Ramírez N; Correig X
PLoS One; 2018; 13(12):e0208908. PubMed ID: 30540827
[TBL] [Abstract][Full Text] [Related]
8. Spatially resolved metabolomic characterization of muscle invasive bladder cancer by mass spectrometry imaging.
Tu A; Said N; Muddiman DC
Metabolomics; 2021 Jul; 17(8):70. PubMed ID: 34287708
[TBL] [Abstract][Full Text] [Related]
9. Molecular Pathological Diagnosis of Thyroid Tumors Using Spatially Resolved Metabolomics.
Huang L; Mao X; Sun C; Li T; Song X; Li J; Gao S; Zhang R; Chen J; He J; Abliz Z
Molecules; 2022 Feb; 27(4):. PubMed ID: 35209182
[TBL] [Abstract][Full Text] [Related]
10. In Situ Metabolomics in Cancer by Mass Spectrometry Imaging.
Buck A; Aichler M; Huber K; Walch A
Adv Cancer Res; 2017; 134():117-132. PubMed ID: 28110648
[TBL] [Abstract][Full Text] [Related]
11. Metabolomic profiling of prostate cancer by matrix assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry imaging using Matrix Coating Assisted by an Electric Field (MCAEF).
Wang X; Han J; Hardie DB; Yang J; Pan J; Borchers CH
Biochim Biophys Acta Proteins Proteom; 2017 Jul; 1865(7):755-767. PubMed ID: 28017863
[TBL] [Abstract][Full Text] [Related]
12. MALDI-TOF MS imaging of metabolites with a N-(1-naphthyl) ethylenediamine dihydrochloride matrix and its application to colorectal cancer liver metastasis.
Wang J; Qiu S; Chen S; Xiong C; Liu H; Wang J; Zhang N; Hou J; He Q; Nie Z
Anal Chem; 2015 Jan; 87(1):422-30. PubMed ID: 25474421
[TBL] [Abstract][Full Text] [Related]
13. Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging: Diagnostic Pathways and Metabolites for Renal Tumor Entities.
Erlmeier F; Sun N; Shen J; Feuchtinger A; Buck A; Prade VM; Kunzke T; Schraml P; Moch H; Autenrieth M; Weichert W; Hartmann A; Walch A
Oncology; 2023; 101(2):126-133. PubMed ID: 36198279
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer diagnosis and characterization with mass spectrometry imaging.
Kurreck A; Vandergrift LA; Fuss TL; Habbel P; Agar NYR; Cheng LL
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):297-305. PubMed ID: 29209003
[TBL] [Abstract][Full Text] [Related]
15. Applications of mass spectrometry imaging in virus research.
Bertzbach LD; Kaufer BB; Karger A
Adv Virus Res; 2021; 109():31-62. PubMed ID: 33934829
[TBL] [Abstract][Full Text] [Related]
16. A graphical data processing pipeline for mass spectrometry imaging-based spatially resolved metabolomics on tumor heterogeneity.
Huang L; Mao X; Sun C; Luo Z; Song X; Li X; Zhang R; Lv Y; Chen J; He J; Abliz Z
Anal Chim Acta; 2019 Oct; 1077():183-190. PubMed ID: 31307708
[TBL] [Abstract][Full Text] [Related]
17. MALDI IMS and Cancer Tissue Microarrays.
Casadonte R; Longuespée R; Kriegsmann J; Kriegsmann M
Adv Cancer Res; 2017; 134():173-200. PubMed ID: 28110650
[TBL] [Abstract][Full Text] [Related]
18. Capillary electrophoresis-mass spectrometry for targeted and untargeted analysis of the sub-5 kDa urine metabolome of patients with prostate or bladder cancer: A feasibility study.
MacLennan MS; Kok MGM; Soliman L; So A; Hurtado-Coll A; Chen DDY
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Feb; 1074-1075():79-85. PubMed ID: 29334632
[TBL] [Abstract][Full Text] [Related]
19. Interplay between post-translational cyclooxygenase-2 modifications and the metabolic and proteomic profile in a colorectal cancer cohort.
Prieto P; Jaén RI; Calle D; Gómez-Serrano M; Núñez E; Fernández-Velasco M; Martín-Sanz P; Alonso S; Vázquez J; Cerdán S; Peinado MÁ; Boscá L
World J Gastroenterol; 2019 Jan; 25(4):433-446. PubMed ID: 30700940
[TBL] [Abstract][Full Text] [Related]
20. MALDI mass spectrometry imaging: A cutting-edge tool for fundamental and clinical histopathology.
Longuespée R; Casadonte R; Kriegsmann M; Pottier C; Picard de Muller G; Delvenne P; Kriegsmann J; De Pauw E
Proteomics Clin Appl; 2016 Jul; 10(7):701-19. PubMed ID: 27188927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
